APXZF Quote, Financials, Valuation and Earnings

BioArctic AB has a net margin of 17.18% compared to Carasent AB's net margin of -65.15%. Carasent AB's return on equity of 0.5% beat BioArctic AB's return on equity of 59.48%.

Carasent AB has a consensus price target of --, signalling downside risk potential of --. On the other hand BioArctic AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Carasent AB has higher upside potential than BioArctic AB, analysts believe Carasent AB is more attractive than BioArctic AB.

Carasent AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioArctic AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Carasent AB has a quarterly dividend of $0.17 per share corresponding to a yield of 0%. BioArctic AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carasent AB pays -- of its earnings as a dividend. BioArctic AB pays out -- of its earnings as a dividend.

Carasent AB quarterly revenues are $8.6M, which are smaller than BioArctic AB quarterly revenues of $14M. Carasent AB's net income of $1.5M is higher than BioArctic AB's net income of -$9.1M. Notably, Carasent AB's price-to-earnings ratio is 705.48x while BioArctic AB's PE ratio is 32.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carasent AB is 9.92x versus 16.63x for BioArctic AB. Usually stocks with elevated PS ratios are considered overvalued.

Camurus AB has a net margin of 17.18% compared to Carasent AB's net margin of 33.97%. Carasent AB's return on equity of 0.5% beat Camurus AB's return on equity of 21.63%.

Carasent AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Camurus AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Carasent AB has higher upside potential than Camurus AB, analysts believe Carasent AB is more attractive than Camurus AB.

Carasent AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Camurus AB has a beta of 0.933, suggesting its less volatile than the S&P 500 by 6.658%.

Carasent AB has a quarterly dividend of $0.17 per share corresponding to a yield of 0%. Camurus AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carasent AB pays -- of its earnings as a dividend. Camurus AB pays out -- of its earnings as a dividend.

Carasent AB quarterly revenues are $8.6M, which are smaller than Camurus AB quarterly revenues of $59.6M. Carasent AB's net income of $1.5M is lower than Camurus AB's net income of $20.2M. Notably, Carasent AB's price-to-earnings ratio is 705.48x while Camurus AB's PE ratio is 53.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carasent AB is 9.92x versus 17.95x for Camurus AB. Usually stocks with elevated PS ratios are considered overvalued.

Hansa Biopharma AB has a net margin of 17.18% compared to Carasent AB's net margin of -481.29%. Carasent AB's return on equity of 0.5% beat Hansa Biopharma AB's return on equity of --.

Carasent AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Hansa Biopharma AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Carasent AB has higher upside potential than Hansa Biopharma AB, analysts believe Carasent AB is more attractive than Hansa Biopharma AB.

Carasent AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Hansa Biopharma AB has a beta of 0.402, suggesting its less volatile than the S&P 500 by 59.764%.

Carasent AB has a quarterly dividend of $0.17 per share corresponding to a yield of 0%. Hansa Biopharma AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carasent AB pays -- of its earnings as a dividend. Hansa Biopharma AB pays out -- of its earnings as a dividend.

Carasent AB quarterly revenues are $8.6M, which are larger than Hansa Biopharma AB quarterly revenues of $3.2M. Carasent AB's net income of $1.5M is higher than Hansa Biopharma AB's net income of -$15.6M. Notably, Carasent AB's price-to-earnings ratio is 705.48x while Hansa Biopharma AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carasent AB is 9.92x versus 12.08x for Hansa Biopharma AB. Usually stocks with elevated PS ratios are considered overvalued.

Orexo AB has a net margin of 17.18% compared to Carasent AB's net margin of -33.67%. Carasent AB's return on equity of 0.5% beat Orexo AB's return on equity of -134.37%.

Carasent AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Orexo AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Carasent AB has higher upside potential than Orexo AB, analysts believe Carasent AB is more attractive than Orexo AB.

Carasent AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Orexo AB has a beta of 0.861, suggesting its less volatile than the S&P 500 by 13.934%.

Carasent AB has a quarterly dividend of $0.17 per share corresponding to a yield of 0%. Orexo AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carasent AB pays -- of its earnings as a dividend. Orexo AB pays out -- of its earnings as a dividend.

Carasent AB quarterly revenues are $8.6M, which are smaller than Orexo AB quarterly revenues of $12.2M. Carasent AB's net income of $1.5M is higher than Orexo AB's net income of -$4.1M. Notably, Carasent AB's price-to-earnings ratio is 705.48x while Orexo AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carasent AB is 9.92x versus 1.31x for Orexo AB. Usually stocks with elevated PS ratios are considered overvalued.